Colloidal properties of biodegradable nanoparticles influence interaction with amyloid-β peptide

Journal of Biotechnology

Volumn 156, Issue 4, 2011, Pages 338-340

  Brambilla, Davide ^a   Souguir, Hayfa ^a   Nicolas, Julien ^a   Mackiewicz, Nicolas ^a   Verpillot, Romain ^a   Le Droumaguet, Benjamin ^a   Taverna, Myriam ^a   Couvreur, Patrick ^a   Andrieux, Karine ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Alzheimer's disease; Amyloid peptide; Nanoparticles; Surface properties

Indexed keywords

CAPILLARY ELECTROPHORESIS; GLYCOPROTEINS; NANOPARTICLES; PEPTIDES; POLYETHYLENE GLYCOLS; SODIUM; SURFACE PROPERTIES;

ALZHEIMER'S DISEASE; AMYLOID-BETA PEPTIDES; BIODEGRADABLE NANOPARTICLE; COLLOIDAL PROPERTIES; LASER INDUCED FLUORESCENCE DETECTION; NANOPARTICULATE SYSTEM; NEGATIVE SURFACE CHARGES; NEURODEGENERATIVE DISORDERS;

NEURODEGENERATIVE DISEASES;

AMYLOID BETA PROTEIN[1-42]; CHOLIC ACID; MACROGOL BLOCK POLYLACTIDE; MACROGOL DERIVATIVE; NANOCARRIER; NANOPARTICLE; POLYLACTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BIODEGRADABILITY; CAPILLARY ELECTROPHORESIS; COLLOID; CONTROLLED STUDY; FLUORESCENCE; KINETICS; LASER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STABILITY; SURFACE PROPERTY;

EID: 82955195853     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.07.020     Document Type: Article

References (11)

1. Aguzzi A., O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 2010, 9:237.
2. Benny O., Fainaru O., Adini A., Cassiola F., Bazinet L., Adini I., Pravda E., Nahmias Y., Koirala S., Corfas G., D'Amato R.J., Folkman J. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat. Biotechnol. 2008, 26:799.
3. Brambilla D., Verpillot R., Taverna M., De Kimpe L., Le Droumaguet B., Nicolas J., Mantegazza F., Canovi M., Gobbi M., Salmona M., Nicolas V., Scheper W., Couvreur P., Andrieux K. New Method Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF) to Monitor Interaction between Nanoparticles and the Amyloid-β Peptide. Anal. Chem. 2010, 82:10083.
4. Brambilla D., Le Droumaguet B., Nicolas J., Hashemi S.H., Wu L.-P., Moghimi S.M., Couvreur P., Andrieux K. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomed. Nanotechnol. Biol. Med. 2011, 10.1016/j.nano.2011.03.008.
5. Findeis M.A. The role of amyloid β peptide 42 in Alzheimer's disease. Pharmacol. Ther. 2007, 116:266.
6. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600.
7. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., Blunk T., Muller R.H. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B Biointerfaces 2000, 18:301.
8. Panza F., Solfrizzi V., Frisardi V., Imbimbo B.P., Capurso C., D'Introno A., Colacicco A.M., Seripa D., Vendemiale G., Capurso A., Pilotto A. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. Aging Clin. Exp. Res. 2009, 21:386.
9. Pierson L.-A., Nicolas J., Lalanne M., Brambilla D., Marsaud V., Nicolas V., Ball R., Stanimirovic D., Couvreur P., Andrieux K. Formulation of didanosine prodrugs into PEGylated poly(alkyl cyanoacrylate) nanoparticles and uptake by brain endothelial cells. J. Nanoneurosci. 2009, 1:174.
10. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329.
11. Wollen K.A. Alzheimer's disease: the Pros and Cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern. Med. Rev. 2010, 15:223.